Rheumatology CRO

Medpace is a premier global CRO for rheumatology, streamlining and accelerating clinical development. 

Medpace is a premier global CRO for rheumatology, streamlining and accelerating clinical development. 

Medpace’s cross-functional team of experts has extensive experience in successfully designing and executing rheumatology trials.

There is a significant unmet need for effective therapies in rheumatic diseases; however, clinical trials in this field present unique challenges, including complex patient recruitment, limited validated outcome measures, complex study designs, and an increasingly competitive landscape. Be confident in the successful design and execution of your rheumatology study by partnering with Medpace experts who have a deep understanding of the complex conditions experienced by patients and the potential barriers that may arise when conducting rheumatology trials.

Medpace’s full-service model, extensive rheumatology experience, and proven track record across various therapeutic areas provide the flexibility necessary to support the unique needs of these studies. Our cross-specialty expertise is critical for managing complex trials in systemic lupus erythematosus, rheumatoid arthritis, spondyloarthropathies, and other rheumatic indications.

Article

Redefining Osteoarthritis Clinical Development

The Emerging Role of DMOADs

Making the Complex Seamless® in Global Rheumatology Clinical Trials

The Medpace rheumatology team has successfully conducted Phase III registration trials leading to marketing authorization of products for systemic autoimmune rheumatic diseases and inflammatory arthropathies. Drive the successful execution of your rheumatology trials with a CRO partner with strong communication, well-established site relationships, and experience collaborating with global regulatory authorities. Medpace can support your clinical trials through:

  • Extensive experience in biosimilars, combination therapies, and new approaches such as:
    • Immunomodulatory biologics
    • Genetically altered cell therapies
    • Gene transfer-mediated immunotherapies
    • Selective Kinase Inhibitors
  • Global regulatory affairs team able to lead, consult, and manage complex regulatory approval processes, along with an experienced regulatory submissions team to support site contract negotiations and expedite start-up
  • Strong, long-term relationships with investigators, experienced sites, networks, and key opinion leaders (KOLs) help facilitate strategic site selection, start-up, and recruitment efforts
  • A flexible and highly-customizable ePRO solution that is fully-integrated into ClinTrak®, Medpace’s proprietary clinical trial management system
  • Strategic guidance from our dedicated, in-house patient recruitment and retention teams who are experienced in recruiting patient populations, including clinical trials in rare rheumatology diseases, such as systemic sclerosis and vasculitis

Integrated Services

Our comprehensive CRO services are supported by our wholly-owned Central Laboratories, Bioanalytical Lab, Imaging and ECG Core Lab, and Phase I Unit, as well as ClinTrak®, a Clinical Trial Management System that ties all study data together in a single platform with client access. 

In-House Therapeutic Expertise

Medpace cross-functional teams of medical, operational, and regulatory experts are actively involved throughout the lifecycle of the project to create effective and efficient study designs for Sponsors of all sizes. Our embedded board-certified rheumatologists and immunologists have a thorough understanding of the complex conditions that cause these diseases, as well as the medical complications experienced by patients. They provide strategic direction for study design and planning, train operational staff, work with Investigators, provide medical monitoring, and meet with regulatory agencies.

Medpace has extensive experience conducting global Phase I-IV rheumatology trials, with expertise across a spectrum of indications, including but not limited to:

  • ANCA-Associated Vasculitis 
  • Giant Cell Arteritis 
  • Hyperuricemia & Gout 
  • Inflammatory Myositis
    • Dermatomyositis
    • Polymyositis 
  • Osteoarthritis 
  • Osteoporosis 
  • Polymyalgia Rheumatica 
  • Psoriatic Arthritis 
  • Rheumatoid Arthritis 
  • Scleroderma / Systemic Sclerosis / Raynaud 
  • Sjögren’s Syndrome 
  • Spondyloarthropathies
    • Non-radiographic axial spondyloarthritis 
    • Radiographic axial spondyloarthritis 
  • Systemic Lupus Erythematosus & Lupus Nephritis 

“Being part of the Medpace medical team allows me to continue to use my medical knowledge in collaboration with a team dedicated to developing exciting and innovative treatments in areas of need, including rheumatology.”

Andrew Head, MD
Medical Director, Mepdace

“Rheumatology research has seen significant advancements, offering more treatment options; however, there still remains an unmet need for several rheumatology conditions. By being involved in the development of safe and effective medical therapeutics, Medpace is offering new hope to patients through treatments that could provide a better quality of life and possibly a cure.”

Maricor Docena, DO
Medical Director, Mepdace